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The following recommendations apply to adult-type soft tissue
sarcomas arising from limbs and superficial trunk.
Recommendations on retroperitoneal sarcomas, desmoid-type
fibromatosis and uterine sarcomas are provided separately at
the end of the chapter with regard to those main aspects by
which they differ from more frequent soft tissue sarcomas. In
general, the main principles of diagnosis and treatment may
well apply to all soft tissue sarcomas, including the rarest
presentations (e.g. visceral sarcomas other than gastrointestinal
stromal tumors (GIST), head and neck sarcomas), which
therefore are not specifically covered. Specific histological types,
however, may deserve specific approaches, which may not be
covered hereafter, given the scope of these Recommendations.
Extraskeletal Ewing’s family tumors and embryonal and
alveolar rhabdomyosarcoma are covered by other ESMO
Clinical Recommendations, inasmuch as they need completely
different approaches. The same applies to GIST.
incidence
Adult soft tissue sarcomas are rare tumors, with an estimated
incidence averaging 4/100 000/year in Europe.
diagnosis
The standard approach to diagnosis consists of multiple core
needle biopsies. However, an excisional biopsy may be the most
practical option for <5 cm superficial lesions. An open biopsy
may be another option in selected cases. The biopsy should be
performed by a trained surgeon, or discussed between the
surgeon and the radiologist. It should be planned in such a way
that the bioptic pathway and the scar can be safely removed on
definitive surgery, and should be preceded by imaging
(contrast-enhanced MRI is the preferred method for limb and
superficial trunk lesions).
Histological diagnosis should be made according to the
WHO classification. The malignancy grade should be provided
in all cases in which this is feasible based on available systems.
In Europe, the Fe´de´ration Nationale des Centres de Lutte
Contre le Cancer (FNLCC) grading system is generally used,
which distinguishes three malignancy grades. A core biopsy
may underestimate the tumor malignancy grade, so that, when
preoperative treatment is an option, radiological imaging may
add to pathology in providing the clinician with information
which helps to estimate the malignancy grade.
Pathologic diagnosis relies on morphology and
immunohistochemistry. It should be complemented by
molecular pathology (FISH, RT–PCR), to be performed in
a laboratory enrolled in an external quality assurance program,
in particular when the clinical pathologic presentation is
unusual, or the histologic diagnosis is doubtful. The tumor
sample should be fixed in formalin (Bouin fixation should be
avoided, since it may impair the feasibility of molecular
analysis). Collection of frozen tissue and tumor imprints (touch
preps) is encouraged, because new molecular pathology
assessments may become available later on and be made in
the patient’s interest. Informed consent for tumor
banking should be sought that allows for later analysis and
research.
Tumor site should be properly recorded. Tumor size and
tumor depth (in relation to the muscular fascia) should be
recorded, since they entail a prognostic value, along with the
tumor malignancy grade.
staging and risk assessment
The pathology report should include an appropriate
description of tumor margins (i.e. the status of inked margins
and the distance between tumor edge and the closest inked
margins). This allows the assessment of marginal status (i.e.
whether the minimum margin is intralesional, marginal, wide,
and which are their distances from surrounding tissues). The
pathologic assessment of margins should be made in
collaboration with the surgeon. The surgical report should
provide details on the surgical conduct with regard to possible
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contaminations (i.e. it should mention whether the tumor was
opened, etc.).
If preoperative treatment was carried out, the pathology
report should include a tumor response assessment. In contrast
to osteosarcoma and Ewing’s family of tumors, however, no
validated system is available at present in this regard, and no
percentage of residual ‘viable cells’ is considered to have
a specific prognostic significance. This depends on some
difficulties, including the presence of non-treatment-related
necrosis and hemorrhage and the heterogeneity of post-
treatment changes. A multidisciplinary judgment is
recommended, involving the pathologist and the radiologist.
A chest CT scan is mandatory for staging purposes.
Depending on the histological type and other clinical features,
further staging assessments may be recommended (e.g. regional
lymph node assessment for synovial sarcoma or epithelioid
sarcoma, abdominal CT scan for myxoid liposarcoma, etc.).
The AJCC/UICC staging classification system stresses the
importance of the malignancy grade in sarcoma. However, its
use in routine practice is limited. In addition to grading, other
prognostic factors are tumor size and tumor depth.
treatment
Soft tissue sarcomas are ubiquitous in their site of origin, and
are often treated with multimodality treatment.
Multidisciplinary treatment planning is therefore mandatory in
all cases (involving pathologists, radiologists, surgeons,
radiation therapists, medical oncologists, pediatric oncologists
if needed). This should be carried out in referral centers for
sarcomas and/or within collaborative networks sharing
multidisciplinary expertise. These centers are involved in
ongoing clinical trials, in which sarcoma patients’ enrolment is
highly encouraged. This centralized referral should be pursued as
from the time of the clinical diagnosis of a suspect sarcoma. In
practice, referral of all patients with a lesion likely to be a sarcoma
would be recommended. Practically, this would mean referring
all patients with a deep mass of soft tissues, or with a superficial
lesion of soft tissues having a diameter of >5 cm.
limited disease
Surgery is the standard treatment for all patients with adult-
type, localized soft tissue sarcomas. It should be performed by
a surgeon trained in the disease. The standard surgical
procedure is a wide excision, complemented by radiation
therapy as standard treatment of deep tumors with a diameter
of >5 cm [II, A]. This implies removing the tumor with a rim of
normal tissue around. One centimeter has been selected as
a cut-off in some studies, but it is important to realize that the
margin can be minimal in the case of resistant anatomic
barriers, such as muscular fasciae, periostium and perineurium.
A marginal excision may be acceptable as an individualized
option in highly selected cases, in particular for
extracompartmental atypical lipomatous tumors. Radiation
therapy as an adjuvant to surgery is an option in selected cases
of deep lesions £5 cm or low-grade tumors. Compartmental
resection of an intracompartmental tumor, if performed, does
not require adjuvant radiation therapy.
Radiation therapy should be administered postoperatively,
with the best technique available, at a dose of 50–60 Gy, with
fractions of 1.8–2 Gy, possibly with boosts up to 66 Gy,
depending on presentation and quality of surgery.
Radiotherapy may be carried out preoperatively normally using
a dose of 50 Gy. IORT and brachytherapy are options in
selected cases.
Data have been provided that adjuvant chemotherapy might
improve, or at least delay, distant and local recurrence in high-
risk patients. A recently reported meta-analysis found a limited
benefit in survival. However, studies are conflicting, and a final
demonstration of efficacy is lacking. Therefore, adjuvant
chemotherapy is not standard treatment in adult-type soft
tissue sarcomas, and can be proposed as an option to the high-
risk individual patient (having a G2–3, deep, >5 cm tumor) for
shared decision-making in conditions of uncertainty [II, C].
The histological type may be considered in the decision-
making, since some types are felt to be more chemosensitive,
while others are less. If the decision is made to use
chemotherapy as upfront treatment, it may well be used
preoperatively, at least in part. A local benefit may be gained,
facilitating surgery. One randomized study provided evidence
that regional hyperthermia in addition to systemic
chemotherapy may be associated with a local and disease-free
survival advantage.
Reoperation should be considered in case of R1 resections, if
adequate margins can be achieved without major morbidity,
taking into account tumor extent and tumor biology (e.g. it
may be spared in extracompartmental atypical lipomatous
tumors, etc.). In the case of R2 surgery, reoperation is
mandatory, possibly with preoperative treatments if adequate
margins cannot be achieved, or surgery is mutilating. In the
latter case, the use of multimodal therapy with less radical
surgery requires shared decision-making with the patient under
conditions of uncertainty. Plastic repairs and vascular grafting
should be used as needed, and the patient should be properly
referred if necessary. Radiation therapy will obviously follow
marginal or R1–2 excisions, if these cannot be rescued through
re-excision, even outside its usual indications.
In non-resectable tumors, or those amenable only to
mutilating surgery (in this case, on an individualized basis after
sharing the decision with the patient in conditions of
uncertainty), chemotherapy and/or radiotherapy, or isolated
hyperthermic limb perfusion with tumor necrosis factor-alpha
(TNFa) + melphalan, if the tumor is confined to an extremity,
or regional hyperthermia combined with chemotherapy are
options.
Regional lymph node metastases should be distinguished
from soft tissue metastases involving lymph nodes. They are
rare, and constitute an adverse prognostic factor in adult-type
soft tissue sarcomas. More aggressive treatment planning is
therefore felt to be appropriate for these patients, although in
the lack of formal evidence that this improves clinical results.
Surgery through wide excision (mutilating surgery is
exceptionally done given the prognosis of these patients) may
be coupled with adjuvant radiation therapy and adjuvant
chemotherapy for sensitive histological types, as standard
treatment for these presentations. Chemotherapy may be
administered as preoperative treatment, at least in part. These
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treatment modalities adding to surgery should not be viewed as
truly ‘adjuvant’, the context being in fact that of a likely
systemic disease. One randomized study provided evidence that
regional hyperthermia in addition to chemotherapy may be
associated with a disease-free survival advantage. Isolated limb
perfusion may be an option in this patient population, along
with chemotherapy and radiation therapy.
The standard approach to local relapses parallels the
approach to primary local disease, except for a wider resort to
preoperative or postoperative radiation therapy, if not
previously performed.
extensive disease
In the case of synchronous lung metastases without
extrapulmonary disease, standard treatment is chemotherapy
[IV, B]. Especially when a tumor response is achieved, surgery
of completely resectable lung metastases may be offered as an
option. Metachronous resectable, and reasonably limited, lung
metastases without extrapulmonary disease are managed with
complete excision of all visible lesions as standard treatment
[IV, B]. Chemotherapy may be added as an option, taking into
account the prognostic factors (a short previous free interval
and a high number of lesions are adverse factors, encouraging
the addition of chemotherapy), although in the lack of formal
evidence that this improves results. Chemotherapy is preferably
given before surgery, in order to assess tumor response and
thus modulate the length of treatment.
Extrapulmonary disease is treated with chemotherapy as
standard treatment [I, A]. In highly selected cases, surgery of
responding metastases, whether pulmonary or possibly
extrapulmonary, may be offered as an option following
a multidisciplinary evaluation, taking into consideration their
site and the natural history of the disease in the single patient.
Best supportive care may be another option in selected cases.
Standard chemotherapy is based on anthracyclines in first-
line treatment [I, A]. There is no formal demonstration that
multiagent chemotherapy is superior to single-agent
chemotherapy with doxorubicin alone. However, a higher
response rate is expected in sensitive histological types.
Therefore, multiagent chemotherapy with doxorubicin plus
ifosfamide may be of choice, especially when a tumor response
is felt to be able to give an advantage and the performance
status is good. Dacarbazine may be added to the regimen. In
angiosarcoma, taxanes are an alternative option, given their
high antitumor activity in this specific histological type [IV, B].
Taxanes are obviously an option also for second-line
chemotherapy in this subtype.
Patients who have already received chemotherapy may be
treated with ifosfamide, if they did not receive it previously.
High-dose ifosfamide may be an option also for patients who
already received standard-dose ifosfamide [IV, C]. Trabectedin
is a second-line option [II, B]. It has proved effective in
leiomyosarcoma and liposarcoma. In myxoid liposarcoma
a peculiar pattern of tumor response has been reported, with an
early phase of tissue changes preceding tumor shrinkage.
Responses have been obtained in other histological types,
including synovial sarcoma. Randomized evidence was
provided that gemcitabine + docetaxel is more effective than
gemcitabine alone as second-line chemotherapy [II, D].
Gemcitabine was shown to have antitumor activity in
leiomyosarcoma also as a single agent. Dacarbazine has some
activity as second-line therapy (possibly mostly in
leiomyosarcoma). Best supportive care is an option for
pretreated patients with advanced soft tissue sarcoma, all the
more if further-line therapies have already been used in the
patient.
Imatinib is standard medical therapy for those rare patients
with dermatofibrosarcoma protuberans who are not amenable
to surgery or with metastases deserving medical therapy [IV, B].
follow-up
There are no published data supporting specific policies for
follow-up of surgically treated patients with localized disease.
Relapses most often occur to the lungs. The malignancy grade
likely affects the speed at which relapses may take place. The
risk assessment based on tumor grade, tumor size and tumor
site may help in choosing the routine follow-up policy. High-
risk patients generally relapse within 2–3 years, while low-risk
patients may relapse later, although it is less likely. Early
detection of local or metastatic recurrence to the lungs may
have prognostic implications, and lung metastases are
asymptomatic at a stage in which they are suitable for surgery.
Therefore, routine follow-up may focus on these sites. The best
method of follow-up has not been established. Although the use
of MRI to detect local relapse and CT to scan for lung
metastases is likely to pick up recurrence earlier, it is still to be
demonstrated that this is beneficial or cost effective compared
with clinical assessment of the primary site and regular chest
X-rays. The surgically treated intermediate–high grade patient
may be followed every 3–4 months in the first 2–3 years, then
twice a year up to the fifth year and once a year thereafter. Low-
grade sarcoma patients may be followed for local relapse every
4–6 months, with chest X-rays or CT scan at more relaxed
intervals, in the first 3–5 years, then yearly.
special presentations and entities
retroperitoneal sarcomas
Core needle biopsies are the standard procedure for diagnosis
also in retroperitoneal sarcomas. An open biopsy may be an
option in selected cases. However, radiological imaging is
sufficient for diagnosis of lipomatous tumors, if no
preoperative treatment is planned.
Standard treatment for localized lesions is surgery, which is
best performed through a retroperitoneal compartmental
resection (i.e. complete excision of the tumor, along with en-bloc
visceral resections) [IV, D]. Preoperative treatment may be an
option, including radiation therapy, chemotherapy,
chemoradiation therapy, regional hyperthermia in addition to
chemotherapy. Adjuvant chemotherapy is an option as for high-
risk localized soft tissue sarcoma of limbs and superficial trunk.
uterine sarcomas
This group includes: leiomyosarcomas, endometrial stromal
sarcomas—low-grade, undifferentiated endometrial sarcomas
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(high-grade endometrial sarcomas) and pure heterologous
sarcomas. Carcinosarcomas (malignant Mullerian mixed
tumors) are mixed epithelial and mesenchymal neoplasms,
whose treatment may fall within the sarcoma domain inasmuch
as their differentiation in the single case is mainly
mesenchymal.
Standard treatment for all these tumors, when localized, is
total abdominal hysterectomy, although, for endometrial
stromal sarcomas—low-grade, bilateral salpingo-
oophorectomy is generally performed, due to the hormonal
sensitivity of these tumors, and lymphadenectomy may be an
option, given the possible higher incidence of nodal
involvement [IV, D]. As far as leiomyosarcomas and high-grade
undifferentiated sarcomas are concerned, bilateral salpingo-
oophorectomy, particularly in premenopausal women, as well
as lymphadenectomy, is not demonstrated to be useful in the
lack of macroscopic involvement. Radiation therapy has
not been shown to improve survival, but has improved
the local relapse rate, so that its use as an adjuvant to surgery
is an option, after shared decision-making with the patient
[III, C].
The systemic treatment of metastatic endometrial stromal
sarcomas—low-grade exploits their sensitivity to hormonal
therapies [V, D]. Therefore, progestins are generally used, along
with Gn-RH analogs and aromatase inhibitors. Tamoxifen is
contraindicated, as well as hormonal replacement therapy
containing estrogens. Surgery of lung metastases is an option,
given the natural history of the disease.
The systemic treatment of leiomyosarcomas, undifferentiated
endometrial sarcomas and pure heterologous sarcomas parallels
that for adult-type soft tissue sarcomas.
desmoid-type aggressive fibromatosis
Standard treatment for primary disease, if amenable to surgery
without significant functional losses, is wide excision [IV, B]. In
those cases in which only marginal excision can be performed,
postoperative radiation therapy is an option, after sharing the
decision with the patient in conditions of uncertainty,
considering the possible occurrence of radiation-related high-
grade sarcomas in a non-metastasizing disease. Observation is
another option in selected cases, after shared decision-making
with the patient, taking into account the indolent natural
history of some clinical presentations.
For primary disease only amenable to surgery with significant
functional losses, wide excision is an option, along with
radiation therapy, observation, isolated limb perfusion (if the
lesion is confined to an extremity) or systemic therapy (see
below) [V, D]. The same applies to recurrent disease.
For the inoperable disease, radiation therapy, ILP (if the
lesion is confined to an extremity), and systemic therapies are
options, along with observation [V, D]. Systemic therapies
include: hormonal therapies (tamoxifen, toremifene, Gn-RH
analogs) 6 NSAIDs; low-dose chemotherapy, such as
methotrexate + vinblastine or methotrexate + vinorelbine;
low-dose interferon; imatinib; full-dose chemotherapy
(using regimens active in sarcomas). It is reasonable
to employ stepwise the less toxic therapies before the more
toxic.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the expert authors and the
ESMO faculty.
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These Clinical Recommendations have been formulated
following a consensus process based on a consensus event
organized by ESMO in Lugano in October 2007 and
a manuscript revision taking place thereafter up to January
2008. The consensus process involved experts from the
community of the European sarcoma research groups and from
some sarcoma centers of excellence outside Europe, indicated
hereafter. The text reflects an overall consensus among them,
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although each of them may not always find it consistent with
his/her own views. The EU-funded network of excellence
CONTICANET (CONnective TIssue CAncers NETwork)
supported the consensus process. The consensus event was
made possible financially by unrestricted grants from Novartis
Oncology, Pfizer Oncology and PharmaMar.
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